| A |
| A. flavus, A. niger, A. fumigatus |
| See Aspergillus Antibody Panel |
| Acid Fast Bacillus Culture Panel (Mycobacterium tuberculosis Culture Panel) |
| Mycobacterial culture and microscopy detection. Susceptibility will be performed at no charge if Mycobacterium tuberculosis is identified. |
| Acid Fast Bacillus Isolate Identification |
| Microscopic analysis and identification of acid fast isolate. |
| Arthropod Identification |
| Microscopic and macroscopic examination to identify parasite (arthropod, insect, tick). |
| Aspergillus Antibody Panel |
| Detection of Aspergillus-specific antibodies to determine recent/active infection |
| B |
| Blastomyces Antibody, Immunodiffusion |
| Detection of Blastomyces-specific antibodies to determine recent/active infection |
| Blood Lead Screening |
| Routine testing for lead exposure in pediatric populations. Elevated results confirmed with venous blood sample. |
| Blood Lead Screening-Venous Sample Follow-up |
| Blood Lead Screening-Venous Sample Follow-up is a confirmatory test when an initial finger stick sample is ≥ 15 µg/dL.
|
| Blood Smear for Parasites |
| Microscopic examination of blood smear for identification of blood parasites. Travel history required to assist diagnosis. If no travel history outside the US in the past 12 months, please note any states visited outside of Iowa. |
| Bordetella pertussis |
| Nucleic acid amplification by PCR to detect Bordetella pertussis DNA |
| Brucella IgG and IgM Antibodies |
| Detection of Brucella IgG and IgM antibodies to determine active and/or past infection |
| C |
| Campylobacter Confirmation Culture |
| Bacterial culture and identification of Campylobacter species |
| Candida auris Colonization Screening |
| Determine carrier status of affected individual. Contact Iowa HHS CADE at (800) 362-2736 to request testing. |
| Candida, cryptococcus |
| See Yeast Isolate Identification |
| Carbapenem Resistant or Carbapenemase Producing Isolate Panel |
| Phenotypic screen of suspected isolates for Carbapenemase production. Identification of unknown bacterial isolate. |
| Carbapenemase-producing organism (CPO) Colonization Screening |
| Determine carrier status of affected individual. State of Iowa Department of Health and Human Services (HHS) approval required for submission. |
| Chlamydia trachomatis/Neisseria gonorrhoeae |
| Nucleic acid amplification by TMA to detect Chlamydia trachomatis and/or Neisseria gonorrhoeae rRNA. |
| Chlamydia pneumoniae PCR |
| Nucleic acid amplification by PCR to detect Chlamydia pneumoniae DNA |
| Coccidioides Antibody, Immunodiffusion |
| Detection of Coccidioides specific antibodies to determine recent/active infection |
| 2019 Novel Coronavirus (COVID-19) Diagnostic Test |
| Nucleic acid amplification by Real-Time PCR or Hologic Aptima SARS-CoV-2 assay (TMA) to detect 2019 Novel Coronavirus RNA |
| COVID-19 IgG Antibody |
| Detection of IgG antibodies against SARS-CoV-2 |
| Cryptococcus Antigen |
| Quantitative detection of antigens of Cryptococcus neoformans in patient serum or Cerebrospinal Fluid (CSF) |
| Cryptosporidium stain |
| See Ova and Parasites (O&P) Exam Panel |
| Cryptosporidium stain, Cyclospora stain, Cystoisospora stain |
| See Modified Acid-Fast Smear for Parasites (Cryptosporidium, Cyclospora, and Cystoisospora Identification) |
| Cystic Fibrosis INSP Related Carrier Screen |
| Screening for up to 23 cystic fibrosis mutations offered to individuals whose family member was identified by the state’s Newborn Screening Program. |
| Cystic Fibrosis Pregnancy Screen Panel |
| Carrier screening for cystic fibrosis mutations for expectant individuals and those planning a pregnancy. Panel of 23 Cystic Fibrosis causing mutations. |
| D |
| Diphtheriae Culture |
| Bacterial culture and identification of Corynebacterium diphtheriae. PCR for diphtheria toxin gene. You MUST call the lab at 319/335-4335 before sending. |
| E |
| E.coli O157 (STEC): Culture Independent Diagnostic Test Panel (PCR or EIA positive stool) |
| See Shiga toxin-producing E. coli (STEC) (O157): Culture Independent Diagnostic Test Panel (PCR or EIA positive stool)
|
| Ehrlichia IgG Antibody Panel (HGA, HME) |
| Detection of IgG antibodies against Human Granulocytic Anaplasmosis (HGA) or Human Monocytic Erlichiosis (HME) |
| Enteric Pathogen Culture Panel |
| Stool culture panel to evaluate for suspected bacterial diarrhea. |
| Enterovirus PCR |
| Nucleic acid amplification by PCR to detect Enterovirus RNA |
| F |
| Fungal Culture |
| Culture to evaluate for suspected fungal disease. This test is for submission of clinical specimens. |
| Fungal Isolate Identification |
| Fungal isolate identification. Methods may include biochemical, DNA probe, or sequencing. |
| Fungal serology |
| See Aspergillus Antibody Panel |
| G |
| Gonorrhea |
| See Neisseria gonorrhoeae culture (test of cure) |
| H |
| H. influenzae Isolate Identification/Serotyping |
| See Reference Isolate Identification Panel (aerobic/microaerophilic) |
| Hepatitis B Surface Antibody |
| Qualitative and quantitative determination of antibody to hepatitis B surface antigen. |
| Hepatitis B Surface Antigen |
| Qualitative detection of hepatitis B surface antigen.
|
| Hepatitis C Antibody |
| Qualitative determination of IgG antibodies to hepatitis C virus. Positive test results are confirmed with supplemental Hepatitis C RNA testing. |
| Hepatitis C Virus Quantitative |
| Hepatitis C Virus Detection and Quantification by NAAT |
| Herpes Simplex Virus PCR (Not Typed) |
| Nucleic acid amplification by PCR to detect Herpes Simplex Virus (1/2) DNA |
| Herpes Simplex Virus Types 1, 2 and Varicella Zoster Virus (VZV) PCR |
| Nucleic acid amplification by PCR to detect human Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV).
|
| Histoplasma Antibody, Immunodiffusion |
| Detection of Histoplasma specific antibodies to determine active and/or past infection |
| HIV 1/2 Antibody Differentiation Supplemental |
| Confirmatory and differential test for the detection of HIV antibodies in patient serum |
| HIV Ag/Ab |
| Screening test for the qualitative detection of HIV p24 antigen and antibodies to HIV-1 (Groups M and O) and HIV-2. Positive test results will be confirmed with a supplemental differentiation test. |
| I |
| Influenza SARS-CoV-2 (Flu SC2) Multiplex |
| Nucleic acid amplification by Real-Time PCR to detect Influenza A and B and SARS-CoV-2 RNA |
| Interferon-Gamma Release Assay for Tuberculosis |
| See QuantiFERON-TB Gold Plus |
| J |
| K |
| L |
| Legionella Culture Panel (includes DFA) |
| Bacterial culture and identification of Legionella pneumophila. Test also includes a DFA smear for Legionella serogroups 1-15. |
| Legionella Multiplex |
| Nucleic acid amplification by PCR to detect Legionella DNA. |
| Listeria Isolate Identification/Serotyping |
| See Reference Isolate Identification Panel (aerobic/microaerophilic) |
| Lyme (Borrelia burgdorferi) Total Antibody |
| Detection of total IgG and IgM antibodies against Lyme disease |
| M |
| Malarial smear |
| See Blood Smear for Parasites |
| Maternal Screen ACHE |
| Not an orderable test. ACHE is a reflex test for a positive Maternal Screen NTD Amniotic Fluid. |
| Maternal Screen First Trimester |
| Screen for Down Syndrome and Trisomy 18 risks in the first trimester of pregnancy. Does not include AFP for Open Neural Tube Defect (NTD) screening. |
| Maternal Screen Integrated |
| Screen for risks of Down Syndrome, Trisomy 18, and Open Neural Tube Defect (NTD) using samples drawn during the first and second trimesters. |
| Maternal Screen Integrated Sample 1 |
| First trimester sample of a 2-part test to screen for risks of Down Syndrome, Trisomy 18, and Open Neural Tube Defect (NTD). |
| Maternal Screen NTD Amniotic Fluid |
| Screen for Open Neural Tube Defect (NTD). Positive result reflexes to Maternal Screen ACHE test for confirmation. |
| Maternal Screen NTD Serum |
| Screen for risk of Open Neural Tube Defect (NTD). |
| Maternal Screen Quad |
| Screen for risks of Down syndrome, Trisomy 18, and Open Neural Tube Defect (NTD). |
| Measles |
| See Rubeola (Measles) IgG Antibody |
| Modified Acid-Fast Smear for Parasites (Cryptosporidium, Cyclospora, and Cystoisospora Identification) |
| Microscopic examination of Modified Acid Fast Stain for coccidian parasites. |
| Mpox Virus |
| The Mpox Virus, Real-Time PCR test is intended for the qualitative detection of mpox virus DNA using swabs from human pustular or vesicular rash specimens. |
| MTB Complex and Rifampin DNA |
| Nucleic acid amplification by Cepheid GeneXpert to detect M. tuberculosis complex and possible resistance to rifampicin treatment. |
| Mumps IgG Antibody |
| Detection of IgG antibodies against Mumps Virus |
| Mumps Virus PCR |
| Nucleic acid amplification by PCR to detect Mumps virus RNA |
| Mycobacterium species culture |
| See Acid Fast Bacillus Culture Panel (Mycobacterium tuberculosis Culture Panel) |
| Mycoplasma pneumoniae |
| Nucleic acid amplification by PCR to detect Mycoplasma pneumoniae DNA |
| N |
| N. meningitidis Isolate Identification/Serotyping |
| See Reference Isolate Identification Panel (aerobic/microaerophilic) |
| Neisseria gonorrhoeae Culture |
| Bacterial culture using selective growth media to isolate Neisseria gonorrhoeae. Routine or Test of Cure. |
| Newborn Screen |
| Screening for certain genetic, endocrine, and metabolic disorders that can affect a child’s long-term health or survival.
Early detection, diagnosis, and intervention can prevent death or disability and enable children to reach their full potential.
|
| Norovirus |
| Nucleic acid amplification by PCR to detect Norovirus RNA |
| Norwalk virus |
| See Norovirus |
| O |
| Ova and Parasites (O&P) Exam Panel |
| Microscopic examination of concentrated sample and trichrome stain for the detection of ova and/or parasites from patient specimens. Travel history required to assist diagnosis. |
| P |
| Parasite Identification |
| Microscopic and macroscopic examination to identify parasite (larvae, worm). |
| Parasite Identification |
| See Arthropod Identification |
| Pinworm Examination |
| Microscopic examination of pinworm collection devices or scotch tape preps for pinworm identification. |
| Q |
| Q-Fever (Coxiella burnetii) IgG Antibody, Phase I & II |
| Detection of IgG antibodies against Coxiella burnetii |
| QuantiFERON-TB Gold Plus |
| Interferon gamma release assay to determine latent Mycobacterium tuberculosis infection |
| R |
| Rabies Virus - Animal Specimen |
| Fluorescent antibody detection of rabies virus in animal brain tissue. Submit animal specimen from possible or confirmed human
exposure.
|
| Rabies Virus - Human Specimen |
| Diagnosis of human rabies infection. Testing performed at CDC. |
| Reference Isolate Identification Panel (aerobic/microaerophilic) |
| Identification of unknown aerobic/microaerophilic isolate. Identification methods may include biochemical testing, spectrometry,
and/or nucleic acid sequence analysis.
|
| Reference Isolate Identification Panel (anaerobic) |
| Identification of unknown anaerobic isolate. Identification methods may include biochemical testing, spectrometry, and/or
nucleic acid sequence analysis.
|
| Rocky Mountain Spotted Fever (Rickettsia rickettsii) IgG Antibody |
| Detection of IgG antibodies against organisms of the appropriate Rickettsial antigen group |
| Rubeola (Measles) IgG Antibody |
| Detection of IgG antibodies against Rubeola virus (Measles) |
| S |
| S. pneumoniae Isolate Identification/Serotyping |
| See Reference Isolate Identification Panel (aerobic/microaerophilic) |
| Salmonella/Shigella culture |
| See Enteric Pathogen Culture Panel |
| Salmonella: Culture Independent Diagnostic Test (PCR or EIA positive stool) |
| Bacterial culture and identification of Salmonella species. For recovery of isolates to assist epidemiological investigations.
This is not a confirmatory test.
|
| Salmonella Isolate Identification/Serotyping |
| Determining the serogroup of Salmonella isolates to assist epidemiological investigations. |
| Sentinel Laboratory Response Network Rule Out |
| Rule out suspected agent of bioterrorism. Requires special biosafety precautions. Call SHL before sending. |
| Shiga toxin-producing E. coli (STEC) (O157): Culture Independent Diagnostic Test Panel (PCR or EIA positive stool) |
| Bacterial culture and identification of Shiga toxin-producing E. coli (STEC) species. Used as a Culture Independent Diagnostic Test on a stool specimen that has been detected positive by PCR or EIA for STEC. It is used for the recovery of isolates to assist epidemiological investigations. This is not a confirmatory test.
|
| Shiga toxin-producing E. coli (STEC) (O157 and non-O157) Isolate Identification/Serotyping |
| Determining the serogroup of Shiga toxin-producing Escherichia coli (STEC) (O157 and non-O157) isolates to assist epidemiological investigations. |
| Shiga toxin-producing E. coli (STEC) Exclusion Culture Panel (Clearance for Childcare/School/Work) |
| Determine carrier status of affected individual. State of Iowa Department of Health and Human Services (HHS) approval required for submission. |
| Shigella: Culture Independent Diagnostic Test (PCR or EIA positive stool) |
| Bacterial culture and identification of Shigella species. For recovery of isolates to assist epidemiological investigations.
This is not a confirmatory test.
|
| Shigella Isolate Identification/Serotyping |
| Determining the serogroup of Shigella isolates to assist epidemiological investigations. |
| Shigella Exclusion Culture (Clearance for Childcare/School/Work) |
| Determine carrier status of affected individual. State of Iowa Department of Health and Human Services (HHS) approval required for submission. |
| Syphilis TPPA |
| Treponema pallidum particle agglutination test (TP-PA). Confirmation test for a negative non-treponemal test method using the reverse syphilis testing algorithm. |
| Syphilis VDRL (CSF) |
| Initial screening test for syphilis for Cerebrospinal Fluid (CSF) samples. Titer given only when Syphilis VDRL test is positive. |
| T |
| TB culture |
| See Acid Fast Bacillus Culture Panel (Mycobacterium tuberculosis Culture Panel) |
| TB smear |
| See Acid Fast Bacillus Isolate Identification |
| Tick Borne Diseases |
| See Ehrlichia IgG Antibody Panel (HGA, HME) |
| Tick Identification |
| See Arthropod Identification |
| Treponema pallidum Antibody (Syphilis, no VDRL reflex) |
| This Treponemal assay is for the qualitative determination of total antibodies to Treponema pallidum. It is to be ordered for confirmation of a non-treponemal test performed by the submitter. In conjuction with non-treponemal laboratory tests and clinical findings, it may aid in the diagnosis of syphilis infection. |
| Treponema pallidum Antibody (Syphilis, with VDRL reflex) |
| This Treponemal assay is for the qualitative determination of total antibodies to Treponema pallidum. In conjuction with non-treponemal laboratory tests and clinical findings, it may aid in the diagnosis of syphilis infection. |
| Tularemia IgG and IgM Antibodies |
| Detection of IgG and IgM antibodies against Francisella tularensis |
| U |
| V |
| Vibrio cholera: Culture Independent Diagnostic Test (PCR positive stool) |
| Bacterial culture and identification of Vibrio species. Used as a Culture Independent Diagnostic Test on a stool specimen that has been detected positive by PCR for Vibrio cholera.
It is used for the recovery of isolates to assist epidemiological investigations. This is not a confirmatory test. Please call the lab at 319/335-4335 in advance.
|
| Vibrio Culture |
| Bacterial culture and identification of Vibrio species. Please call the lab at 319/335-4335 in advance. |
| W |
| West Nile Virus IgM Antibody |
| Detection of IgM antibodies against West Nile Virus (active infection) |
| Whooping Cough Culture |
| See Bordetella pertussis |
| X |
| Y |
| Yeast Isolate Identification Panel |
| Identification of Yeast organisms, including Candida and Cryptococcus, by MALDI-TOF Spectrometry. |
| Yersinia Culture |
| Bacterial culture and identification of Yersinia species. |
| Z |